Higher cell surface expression levels of TRAIL-R2 was shown to be associated with the preferential response of ovarian, colon and renal cancer cells lines to TRAIL-R2 agonistic antibodies [42]–[45]. This evidence concerns the gene TNFRSF10B and renal carcinoma.